“Xavo remains open for business while focusing on keeping everybody safe”
Chief Operating Officer
The global coronavirus pandemic presents a challenge to families, communities, businesses, and our globalized society at an unprecedented scale. Our hearts go out to all affected by COVID19, either directly or indirectly.
Like millions of other companies, Xavo has made the health and well-being of their employees, customers, and prospects a top priority. As an Enterprise Software company whose product is delivered as SaaS via the cloud, it is possible for Xavo to remain open for business and to continue to deliver on its commitments, while ensuring the safety of everybody involved. ‘Working from home’ has become the new normal and technology allows us to communicate efficiently within the team as well as with partners and customers.
It is important for us to be able to continue our work – because among Xavo’s valued Pharma and Biopharma customers are many of the industry’s top players as well as younger Biotech companies that are directly involved in the fight against the virus. It is our customers’ mission to find both a cure for the COVID-19 disease as well as a vaccine against the coronavirus itself, and, to find it as quickly as possible.
“Time is of the essence in the fight against COVID-19. And it’s that time to value in Pharma and Biopharma R&D that keeps us up at night”
Chief Executive Officer
Time is of the essence when new medicine is being developed and it has always been. But it’s never been so visible and felt by millions as the world is waiting to come out of lockdown. Shortening the time to value in developing a new drug that can make this happen is what keeps everybody up at night. That is why Xavo has made its customers’ mission its own – to provide software that can help significantly accelerate the time to value in all parts of the R&D value chain, from from basic research into drug discovery/development, to pre-clinical and clinical trials. We do this so that new biological and chemical entities can be developed faster and new medicines can be brought into production and to patients earlier.
It’s the one thing that keeps us up at night – time to value. Xavo has demonstrated that by using its applications at the various stages of the Pharma and Biopharma R&D value chain, the time it takes to develop new entities and to bring them to market faster can be significantly reduced.
As the search for a COVID-19 cure and the race to develop a vaccine continues, it is important for all of us that the Pharma and Biopharma R&D value chain stays operational and that it keeps accelerating the time to value for all molecular entities that might help. Xavo will support its Biopharma customers wherever they rely on our products and services as a critical part of their Digital infrastructure. We would like to assure them of our commitment to the continuity of our services and support so they can be successful in their mission.
Should you have any question or comment about our COVID-19 crisis response efforts, or if you are part of the Pharma and Biopharma R&D community and would like to learn more about how to systematically accelerate your time to value, please contact us.